# Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC

> **NCT06816966** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Fujian Medical University Union Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **RADIATION:** split-course adaptive hypofractionated radiotherapy

## Key facts

- **NCT ID:** NCT06816966
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-12-26
- **Primary completion:** 2026-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06816966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06816966, "Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06816966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*